Brief: Clovis Oncology's Rubraca Met The Primary Endpoint In Phase 3 Treatment Study In Later-Line Ovarian Cancer Patients With A Brca Mutation

Clovis Oncology

21/12/2020 16:31

Dec 21 (Reuters) - Clovis Oncology Inc  CLVS.O :
    * CLOVIS ONCOLOGY’S RUBRACA® (RUCAPARIB) MET THE PRIMARY
ENDPOINT
OF SIGNIFICANTLY IMPROVING PROGRESSION-FREE SURVIVAL VERSUS.
CHEMOTHERAPY IN THE ARIEL4 RANDOMIZED PHASE 3 TREATMENT STUDY IN
LATER-LINE OVARIAN CANCER PATIENTS WITH A BRCA MUTATION
    * CLOVIS ONCOLOGY INC - SAFETY OF RUBRACA OBSERVED IN ARIEL4
STUDY
WAS HIGHLY CONSISTENT WITH BOTH U.S. AND EU LABELS

Source text for Eikon:  ID:nBw3bBjSqa 
Further company coverage:  CLVS.O 

 ((Reuters.Briefs@thomsonreuters.com;))